Physician profile
Muhammad A Raza
NPI 1881661593
$536.82
in general payments reported to CMS, 2019-2025
15 companies · $172 in 2025
The $172 reported for 2025 was less than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.82 · 2020: $35.75 · 2022: $14.67 · 2023: $33.41 · 2024: $265 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $470.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $157.14 | 2024-2025 | Daxxify |
| Inspire Medical Systems, INC. | $51.97 | 2024-2025 | Inspire |
| Tactile Systems Technology INC | $48.24 | 2023-2024 | Entre Plus, Flexitouch Plus |
| Pfizer INC. | $35.71 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $35.23 | 2019-2023 | Tezspire |
| Glaxosmithkline, LLC. | $30.78 | 2024 | Trelegy Ellipta |
| Pinnacle Biologics, INC | $27.79 | 2024 | Photofrin |
| Grifols USA, LLC | $24.93 | 2024 | Prolastin-C Liquid |
| Beigene USA, INC. | $24.77 | 2024 | Brukinsa |
| Allergan, INC. | $22.61 | 2020 | |
| Amgen INC. | $20.07 | 2025 | Tezspire |
| Electromed, INC. | $16.25 | 2024 | Smartvest |
| Genentech USA, INC. | $14.67 | 2022 | |
| Baxter Healthcare | $13.52 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Insmed, INC. | $13.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Raza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.